News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karyopharm Therapeutics (KPTI) Announces A Phase 1 Trial Of Selinexor (KPT-330) In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL) And Acute Myeloid Leukemia (AML)


4/21/2014 9:12:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, Mass., April 21, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of its first pediatric clinical study, a Phase 1 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in pediatric patients. The trial will enroll up to 28 children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML). The study is being led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center under the direction of principal investigator Andrew Place, MD, PhD, Associate Director of Developmental Therapeutics, and has been partially funded by a grant from the William Lawrence & Blanche Hughes Foundation (clinicaltrials.gov: NCT02091245).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES